US 5204114A
· Demopoulos et al.
· 1993
[cited by applicant]
US 5922345A
· Horrobin et al.
· 1999
[cited by applicant]
US 6159500A
· Demopoulos et al.
· 2000
[cited by applicant]
US 6444432B1
· Kleinfeld
· 2002
[cited by applicant]
US 20050192210A1
· Rothbard et al.
· 2005
[cited by applicant]
US 20050192229A1
· Perricone
· 2005
[cited by applicant]
CN 1408427A
· 2003
[cited by applicant]
CN 1748785A
· 2006
[cited by applicant]
CN 101027078A
· 2007
[cited by applicant]
CN 101703813A
· 2010
[cited by applicant]
JP H04074135A
· 1992
[cited by applicant]
JP 2001507696A
· 2001
[cited by applicant]
JP 2008531579A
· 2008
[cited by applicant]
WO WO1997016983A1
· 1997
[cited by applicant]
WO WO2008129851A1
· 2008
[cited by applicant]
WO WO2013122188A1
· 2013
[cited by applicant]
Adachi et al., “Decreased aortic glutathione levels may contribute to impaired nitric oxide-induced relaxation in hypercholesterolaemia,”
[cited by applicant]
Atakishi et al., “Effects of Reduced Glutathione on Nitric Oxide Level, Total Antioxidant and Oxidant Capacity and Adenosine Deaminase Activity,”
[cited by applicant]
Arjinpathana et al., “Glutathione as an oral whitening agent: a randomized, double-blind, placebo-controlled study,”
[cited by applicant]
Aronow et al., “Prevalence of Coexistence of Coronary Artery Disease, Peripheral Arterial Disease, and Atherothrombotic Brain Infarction in Men and Women ≥ 62 Years of Age,”
[cited by applicant]
Brass et al., “Acquired skeletal muscle metabolic myopathy in atherosclerotic peripheral arterial disease,”
[cited by applicant]
Chanséaume et al., “Potential Mechanisms of Muscle Mitochondrial Dysfunction in Aging and Obesity and Cellular Consequences,”
[cited by applicant]
Cheung et al., “Glutathione causes coronary vasodilation via a nitric oxide- and soluble guanylate cyclase-dependent mechanism,”
[cited by applicant]
Fujii et al., “Kino Sokyugata Kobo Ekisu no Oyo to Tekai,”
[cited by applicant]
Ghigo et al., “Nitric oxide synthesis is impaired in glutathione-depleted human umbilical vein endothelial cells,”
[cited by applicant]
Ghigo et al., “Correlation between nitric oxide synthase activity and reduced glutathione level in human and murine endothelial cells,”
[cited by applicant]
Haas et al., “Exercise Training and Peripheral Arterial Disease,”
[cited by applicant]
Hayashi et al., “l-Citrulline and l-arginine supplementation retards the progression of high-cholesterol-diet-induced atherosclerosis in rabbits,”
[cited by applicant]
Henry, “Mechanisms of Changes in Basal Metabolism During Ageing,”
[cited by applicant]
Hien et al., “Analysis of Pomelo Value Chain in Ben Tre Province,”
[cited by applicant]
Kerksick et al., “The antioxidant role of glutathione and N-acetyl-cysteine supplements and exercise-induced oxidative stress,”
[cited by applicant]
Martina et al., “Administration of glutathione in patients with type 2 diabetes mellitus increases the platelet constitutive nitric oxide synthase activity and reduces PAI-1,”
[cited by applicant]
Misner, “Intravenous Glutathione Enhances Cycling Time Trial Performance (A Case Study),” originally published as “Does Glutathione Enhance Exercise Performance?—A Case Study,”
[cited by applicant]
Ochiai et al., “Short-term effects of L-citrulline supplementation on arterial stiffness in middle-aged men,”
[cited by applicant]
Prasad et al., “Glutathione reverses endothelial dysfunction and improves nitric oxide bioavailability,”
[cited by applicant]
Sugimura et al., “Effect of orally administered reduced- and oxidized-glutathione against acetaminophen-induced liver injury in rats,”
[cited by applicant]
Vanhatalo et al., “Dietary nitrate reduces muscle metabolic perturbation and improves exercise tolerance in hypoxia,”
[cited by applicant]
Zhijun et al., “Effect of Reduced Glutathione on hsCRP and Vascular Endothelial Function of Patients with Essential Hypertension,”
[cited by applicant]
Zizola et al., “Metabolic and structural impairment of skeletal muscle in heart failure,”
[cited by applicant]
Canadian Intellectual Property Office, Office Action in Canadian Patent Application No. 2,898,416 (Sep. 23, 2019).
[cited by applicant]
China National Intellectual Property Administration, Notification of First Office Action in Chinese Patent Application No. 201480005570.8 (Aug. 12, 2016).
[cited by applicant]
China National Intellectual Property Administration, The Fourth Office Action in Chinese Patent Application No. 201480005570.8 (Dec. 23, 2021).
[cited by applicant]
European Patent Office, Partial Supplementary European Search Report in European Patent Application No. 14740411.5 (Dec. 9, 2016).
[cited by applicant]
Japanese Patent Office, International Search Report in International Patent Application No. PCT/JP2014/051102 (Apr. 22, 2014).
[cited by applicant]
U.S. Appl. No. 14/762,108, filed Jul. 20, 2015, Pending.
[cited by applicant]
Canadian Intellectual Property Office, Office Action in Canadian Application No. 2,898,416 (Jun. 12, 2024).
[cited by applicant]